Loading...
•
Jun 30, 2022
Centessa Q2 2022 Earnings Report
Reported financial results and business highlights for the second quarter of 2022.
Key Takeaways
Centessa Pharmaceuticals reported its Q2 2022 financial results, highlighting the advancement of its rare diseases and immuno-oncology pipeline. The company is on track to initiate registrational studies for SerpinPC for Hemophilia B in the second half of the year and plans to initiate clinical trials with LB101 for solid tumors after an IND filing later this year. However, they discontinued development of ZF874 following an adverse event.
Registrational studies of SerpinPC for treatment of Hemophilia B planned for 2H of 2022.
Oncology pipeline advancing with novel LockBody® technology.
Discontinued ZF874 for AATD.
Multiple clinical PoC readouts expected across pipeline over next two years.
Centessa
Centessa
Forward Guidance
Centessa Pharmaceuticals expects to reach several milestones, including initiating registrational studies for SerpinPC in Hemophilia B, presenting two-year follow-up data from a Phase 2a open-label extension study for SerpinPC, and submitting an IND for LB101.
Positive Outlook
- Initiate registrational studies in Hemophilia B in 2H 2022.
- Report two-year follow-up data from Phase2a open label extension study for SerpinPC in Q4 2022.
- Submit IND for LB101 in Q4 2022.
- Advance earlier stage programs and provide updates as they enter clinical studies.
- Cash runway into 2026.
Challenges Ahead
- Discontinuation of ZF874 development.
- Adverse event involving elevated liver enzymes (AST/ALT) in a subject dosed with ZF874.
- Unlikely to achieve the desired target product profile with ZF874.
- Analyzing data from the Phase 1 study to help inform potential future development plans for back-up compounds.
- Potential future development plans for back-up compounds are uncertain.